Gour Medical SA Acquires Worldwide Rights to a Dual Orexin Receptor Antagonist for Potential Use in the Veterinary Field

March 10, 2015 09:00 AM Eastern Daylight Time
ZUG, Switzerland--(BUSINESS WIRE)--Gour Medical SA, a veterinary biomedical company, today announced that it has entered into a definitive worldwide license agreement with Actelion Pharmaceuticals Ltd for the veterinary development of one of Actelion's early-stage clinical dual orexin receptor antagonists, which the company had decided not to pursue further.

Gour plans to develop the compound and eventually bring to the market a new treatment to reduce anxiety, hypervigilance and restlessness in dogs during stress situations related to transport, loud noises and separation, a very large and still highly unmet medical need.

Under the terms of the agreement Actelion will receive an upfront payment and will be eligible to receive further payments subject to potential development and regulatory milestones, as well as royalties on sales if the compound is commercialized.

Gour plans to conduct a proof-of-concept study to establish the efficacy of the compound in reducing anxiety, hypervigilance and restlessness in dogs during transport.

About Gour Medical SA

Gour Medical SA , founded in 2014, is a Swiss based veterinary biomedical company leveraging the advances in human research and applying them to medical solutions for companion animals. Integrated and innovative therapeutic solutions developed by Gour address companion animals' unmet medical needs by treating or preventing their most significant health issues.

For more information on Gour, please visit www.gour-medical.com

Contacts
Gour Medical SA
Serge Goldner, CEO
+41 435 08 00 72
[email protected]

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…